<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01047436</url>
  </required_header>
  <id_info>
    <org_study_id>ART003</org_study_id>
    <nct_id>NCT01047436</nct_id>
  </id_info>
  <brief_title>Efficacy of ArTiMist™ in Children</brief_title>
  <official_title>An Open Label Randomised Comparative Trial to Establish the Efficacy of 3 mg/kg ArTiMist™ When Compared to Intravenous Quinine in Children With Severe or Complicated Falciparum Malaria, or Uncomplicated Falciparum Malaria With Gastrointestinal Complications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Proto Pharma Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Xidea Solutions Limited</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Proto Pharma Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy of Artemether Sublingual Spray
      (ArTiMist™) with intravenous quinine in children with severe or complicated falciparum
      malaria, or children with uncomplicated malaria with gastrointestinal complications.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Parasitological Success Defined as a Reduction in Parasite Count of ≥ 90% of Baseline at 24 Hours After the First Dose</measure>
    <time_frame>24 hours after first dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time for Parasite Count to Fall by 90% PCT(90)</measure>
    <time_frame>3h (hours), 6h, 12h, 18h, 24h, 30h, 36h, 48h, 54h, 60h</time_frame>
    <description>The time taken for the parasite count to fall 90% from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time for Parasite Count to Fall by 50% PCT(50)</measure>
    <time_frame>3 h (hours) , 6h, 12h, 18h, 24h, 30h, 36h, 48h, 54h, 60h</time_frame>
    <description>The time taken for the parasite count to fall 50% from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parasite Clearance Time</measure>
    <time_frame>3h (hours), 6h, 12h, 18h, 24h, 30h, 36h, 48h, 54h, 60h</time_frame>
    <description>Time in hours from the initiation of therapy until the first of two successive parasite-negative smears were obtained</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parasite Reduction Ratio (PRR) at 24 h (Hours) After the First Dose</measure>
    <time_frame>24 hours after first dose</time_frame>
    <description>Reduction in parasitaemia from baseline at 24 h after the first dose of study medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parasite Reduction Ratio (PRR) at 12 Hours After the First Dose</measure>
    <time_frame>12 h (hours) after first dose</time_frame>
    <description>Reduction in parasitaemia from baseline at 12 hours after the first dose of study medication</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Falciparum Malaria</condition>
  <arm_group>
    <arm_group_label>ArTiMist (artemether sublingual spray)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous Quinine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quinine</intervention_name>
    <description>20 mg/kg intravenous quinine loading dose, followed by 10 mg/kg intravenously every 8 hours until resumption of normal oral therapy</description>
    <arm_group_label>Intravenous Quinine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artemether</intervention_name>
    <description>Artemether sublingual spray 3 mg/kg at protocol specified timepoints until resumption of normal oral therapy</description>
    <arm_group_label>ArTiMist (artemether sublingual spray)</arm_group_label>
    <other_name>ArTiMist™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The patient's parent or attendant relative has provided informed consent and the
             patient has assented (where relevant) to participation in the trial

          2. The patient is a child that weighs between 5 and 15 kg (kilogram)

          3. The patient has falciparum malaria as evidenced by

               1. Thick or thin blood smears of &gt; 500 P falciparum per mcl (microlitre)(patients
                  with mixed infections may be included provided &gt;500 P Falciparum /mcl) and /or

               2. Positive RDT (rapid diagnostic test)for malaria

          4. The patient has either

               1. severe or complicated malaria as determined by the Investigator based on the WHO
                  criteria for severity, or

               2. the patient has uncomplicated malaria but is unable to tolerate oral medication
                  as a result of gastrointestinal complications such as vomiting or diarrhoea.

        Exclusion Criteria:

          1. Attending relative or parent does not provide informed consent for participation, or
             the child if capable does not assent to participation in the trial.

          2. Ability to tolerate oral therapy

          3. Patient has received any treatment with an artemisinin or quinine in the last 24 hours

          4. Patient has evidence of significant co-infections (this does not include mixed
             Plasmodium infections).

          5. Patient is allergic or intolerant to artemisinins.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daryl Bendel, MBChB MBA Dip Pharm Med MFPM</last_name>
    <role>Study Director</role>
    <affiliation>Xidea Solutions Limited</affiliation>
  </overall_official>
  <removed_countries>
    <country>Rwanda</country>
  </removed_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2010</study_first_submitted>
  <study_first_submitted_qc>January 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2010</study_first_posted>
  <results_first_submitted>September 29, 2010</results_first_submitted>
  <results_first_submitted_qc>December 13, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 14, 2011</results_first_posted>
  <last_update_submitted>January 26, 2011</last_update_submitted>
  <last_update_submitted_qc>January 26, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2011</last_update_posted>
  <responsible_party>
    <name_title>Mr Clive Booles Director of Development</name_title>
    <organization>ProtoPharma</organization>
  </responsible_party>
  <keyword>Plasmodium infections</keyword>
  <keyword>Remittent fever</keyword>
  <keyword>Artemether</keyword>
  <keyword>Artemisinins</keyword>
  <keyword>quinine</keyword>
  <keyword>Malaria</keyword>
  <keyword>Protozoan Infections</keyword>
  <keyword>Anti-Infective Agents</keyword>
  <keyword>Antiprotozoal Agents</keyword>
  <keyword>Schistosomicides</keyword>
  <keyword>Pharmacologic Actions</keyword>
  <keyword>Malaria, Falciparum</keyword>
  <keyword>Antimalarials</keyword>
  <keyword>Antiparasitic Agents</keyword>
  <keyword>Parasitic Diseases</keyword>
  <keyword>sublingual</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Artemether</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
    <mesh_term>Quinine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited at a single study centre in Rwanda during December 2009.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>ArTiMist</title>
          <description>Artemether Sublingual Spray 3 mg/kg administered at 0, 8, 24, 36, 48, and 60 hours</description>
        </group>
        <group group_id="P2">
          <title>Intravenous Quinine</title>
          <description>Intravenous Quinine. Loading dose of 20 mg/kg and subsequent doses of 10 mg/kg 8 hourly</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ArTiMist</title>
          <description>Artemether Sublingual Spray 3 mg/kg administered at 0, 8, 24, 36, 48, and 60 hours</description>
        </group>
        <group group_id="B2">
          <title>Intravenous Quinine</title>
          <description>Intravenous Quinine. Loading dose of 20 mg/kg and subsequent doses of 10 mg/kg 8 hourly</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.03" spread="1.50"/>
                    <measurement group_id="B2" value="3.64" spread="2.46"/>
                    <measurement group_id="B3" value="3.32" spread="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Rwanda</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Parasitological Success Defined as a Reduction in Parasite Count of ≥ 90% of Baseline at 24 Hours After the First Dose</title>
        <time_frame>24 hours after first dose</time_frame>
        <population>For the efficacy endpoints, the analysis was based on the Full Analysis Set (FAS) which was defined as all patients that received at least 1 dose of trial medication and had at least 1 post dose parasite count at 12 h (hours) or 24 h after start of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>ArTiMist</title>
            <description>Artemether Sublingual Spray 3 mg/kg administered at 0, 8, 24, 36, 48, and 60 hours</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Quinine</title>
            <description>Intravenous Quinine. Loading dose of 20 mg/kg and subsequent doses of 10 mg/kg 8 hourly</description>
          </group>
        </group_list>
        <measure>
          <title>Parasitological Success Defined as a Reduction in Parasite Count of ≥ 90% of Baseline at 24 Hours After the First Dose</title>
          <population>For the efficacy endpoints, the analysis was based on the Full Analysis Set (FAS) which was defined as all patients that received at least 1 dose of trial medication and had at least 1 post dose parasite count at 12 h (hours) or 24 h after start of treatment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The sample size was not statistically determined in this initial trial with ArTimist. For the primary outcome analysis, the percentage of patients defined as having success were determined. The difference between ArTiMist and quinine, along with its 95% confidence interval (CI) were determined. The difference between treatments were compared using Fisher’s Exact test</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.17</p_value>
            <method>Fisher Exact</method>
            <param_type>difference between treatments</param_type>
            <param_value>26.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>53.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Parasite Clearance Time</title>
        <description>Time in hours from the initiation of therapy until the first of two successive parasite-negative smears were obtained</description>
        <time_frame>3h (hours), 6h, 12h, 18h, 24h, 30h, 36h, 48h, 54h, 60h</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ArTiMist</title>
            <description>Artemether Sublingual Spray 3 mg/kg administered at 0, 8, 24, 36, 48, and 60 hours</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Quinine</title>
            <description>Intravenous Quinine. Loading dose of 20 mg/kg and subsequent doses of 10 mg/kg 8 hourly</description>
          </group>
        </group_list>
        <measure>
          <title>Parasite Clearance Time</title>
          <description>Time in hours from the initiation of therapy until the first of two successive parasite-negative smears were obtained</description>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.7" spread="41.97"/>
                    <measurement group_id="O2" value="51.2" spread="79.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time for Parasite Count to Fall by 90% PCT(90)</title>
        <description>The time taken for the parasite count to fall 90% from baseline</description>
        <time_frame>3h (hours), 6h, 12h, 18h, 24h, 30h, 36h, 48h, 54h, 60h</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ArTiMist</title>
            <description>Artemether Sublingual Spray 3 mg/kg administered at 0, 8, 24, 36, 48, and 60 hours</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Quinine</title>
            <description>Intravenous Quinine. Loading dose of 20 mg/kg and subsequent doses of 10 mg/kg 8 hourly</description>
          </group>
        </group_list>
        <measure>
          <title>Time for Parasite Count to Fall by 90% PCT(90)</title>
          <description>The time taken for the parasite count to fall 90% from baseline</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6" spread="7.34"/>
                    <measurement group_id="O2" value="19.8" spread="13.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The time for the parasite count to fall by 90% (PCT90) was determined for each patient as the time in minutes/seconds, when the parasite count fell by 90% The PCT90 was appropriately summarised for each treatment for the FAS . The times were presented graphically for each endpoint using a life-table curve (Kaplan-Meier method). For each endpoint the survival curves were compared by the log-rank test. The hazard ratio was calculated along with its 95% CI.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.70</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.48</ci_lower_limit>
            <ci_upper_limit>3.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Parasite Reduction Ratio (PRR) at 24 h (Hours) After the First Dose</title>
        <description>Reduction in parasitaemia from baseline at 24 h after the first dose of study medication</description>
        <time_frame>24 hours after first dose</time_frame>
        <population>For the efficacy endpoints, the analysis was based on the Full Analysis Set (FAS) which was defined as all patients that received at least 1 dose of trial medication and had at least 1 post dose parasite count at 12 h or 24 h</population>
        <group_list>
          <group group_id="O1">
            <title>ArTiMist</title>
            <description>Artemether Sublingual Spray 3 mg/kg administered at 0, 8, 24, 36, 48, and 60 hours</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Quinine</title>
            <description>Intravenous Quinine. Loading dose of 20 mg/kg and subsequent doses of 10 mg/kg 8 hourly</description>
          </group>
        </group_list>
        <measure>
          <title>Parasite Reduction Ratio (PRR) at 24 h (Hours) After the First Dose</title>
          <description>Reduction in parasitaemia from baseline at 24 h after the first dose of study medication</description>
          <population>For the efficacy endpoints, the analysis was based on the Full Analysis Set (FAS) which was defined as all patients that received at least 1 dose of trial medication and had at least 1 post dose parasite count at 12 h or 24 h</population>
          <units>Percent reduction</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="77" upper_limit="100"/>
                    <measurement group_id="O2" value="96.9" lower_limit="53" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time for Parasite Count to Fall by 50% PCT(50)</title>
        <description>The time taken for the parasite count to fall 50% from baseline</description>
        <time_frame>3 h (hours) , 6h, 12h, 18h, 24h, 30h, 36h, 48h, 54h, 60h</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ArTiMist</title>
            <description>Artemether Sublingual Spray 3 mg/kg administered at 0, 8, 24, 36, 48, and 60 hours</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Quinine</title>
            <description>Intravenous Quinine. Loading dose of 20 mg/kg and subsequent doses of 10 mg/kg 8 hourly</description>
          </group>
        </group_list>
        <measure>
          <title>Time for Parasite Count to Fall by 50% PCT(50)</title>
          <description>The time taken for the parasite count to fall 50% from baseline</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0" spread="6.48"/>
                    <measurement group_id="O2" value="10.8" spread="7.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The PCT50 was determined for each patient as the time in minutes/seconds, when the parasite count fell by 50% The PCT50 was appropriately summarised for each treatment for the FAS . The times were presented graphically for each endpoint using a life-table curve (Kaplan-Meier method). For each endpoint the survival curves were compared by the log-rank test. The hazard ratio was calculated along with its 95% CI.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.76</p_value>
            <p_value_desc>Difference between survival curves compared by Log Rank test</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.34</ci_lower_limit>
            <ci_upper_limit>2.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Parasite Reduction Ratio (PRR) at 12 Hours After the First Dose</title>
        <description>Reduction in parasitaemia from baseline at 12 hours after the first dose of study medication</description>
        <time_frame>12 h (hours) after first dose</time_frame>
        <population>For the efficacy endpoints, the analysis was based on the Full Analysis Set (FAS) which was defined as all patients that received at least 1 dose of trial medication and had at least 1 post dose parasite count at 12 h or 24 h</population>
        <group_list>
          <group group_id="O1">
            <title>ArTiMist</title>
            <description>Artemether Sublingual Spray 3 mg/kg administered at 0, 8, 24, 36, 48, and 60 hours</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Quinine</title>
            <description>Intravenous Quinine. Loading dose of 20 mg/kg and subsequent doses of 10 mg/kg 8 hourly</description>
          </group>
        </group_list>
        <measure>
          <title>Parasite Reduction Ratio (PRR) at 12 Hours After the First Dose</title>
          <description>Reduction in parasitaemia from baseline at 12 hours after the first dose of study medication</description>
          <population>For the efficacy endpoints, the analysis was based on the Full Analysis Set (FAS) which was defined as all patients that received at least 1 dose of trial medication and had at least 1 post dose parasite count at 12 h or 24 h</population>
          <units>Percent reduction</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.6" lower_limit="-220" upper_limit="100"/>
                    <measurement group_id="O2" value="75.9" lower_limit="-58" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from the start of the study (01 December 2009) to the last study follow up visit on 19 January 2010</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ArTiMist</title>
          <description>Artemether Sublingual Spray 3 mg/kg administered at 0, 8, 24, 36, 48, and 60 hours</description>
        </group>
        <group group_id="E2">
          <title>Intravenous Quinine</title>
          <description>Intravenous Quinine. Loading dose of 20 mg/kg and subsequent doses of 10 mg/kg 8 hourly</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Malaria reinfection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoae</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Malaria reinfection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PI was restricted from publishing results for 6 months from the end of the trial. This has now passed and the PI is free to publish the results without restriction</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr D Bendel</name_or_title>
      <organization>Xidea Solutions Limited</organization>
      <email>daryl@xideasolutions.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

